Consenso Brasileiro de Esofagite Eosinofílica: Documento Conjunto da Sociedade Brasileira de Pediatria e Associação Brasileira de Alergia e Imunologia

Cristina Targa Ferreira; Elisa de Carvalho; Carlos Marcelo Timossi; Luciana Rodrigues Silva; Maria do Carmo Barros de Melo; Marise Helena Cardoso Tófoli; Amália Maria Porto Lustosa; Ana Paula Beltran Moschione Castro; Antonio Carlos Pastorino; Ariana Campos Yang; Bruno Acatauassu Paes Barreto; Cibele Dantas Marques; Clóvis Francisco Constantino; Cristina Palmer Barros; Erica Rodrigues Mariano de Almeida Rezende; Fabiane Pomiecinski Frota; Fábio Kuschnir; Fátima Rodrigues Fernandes; Germana Pimentel Stefani; Gustavo Falbo Wandalsen; Helen Santos Osterne; Hildenia Ribeiro; Ingrid Pimentel Cunha Magalhães Souza Lima; Jackeline Motta Franco; José Carlison Santos de Oliveira; José Luiz de Magalhães Rios; José Vicente Spolidoro; Katia Brandt; Luciana Ribeiro; Lucila Camargo Lopes de Oliveira; Luiza Salgado Nader; Margarida Antunes; Mário César Vieira; Mauro Batista de Morais; Mauro Sérgio Toporovski; Natalia Rocha do Amaral Estanislau; Norma Mota de Paula Rubini; Renan Augusto Pereira; Renata Rodrigues Cocco; Ricardo Toma; Roberta Paranhos Fragoso; Rose Marcelino; Simone Carvalho; Herberto José Chong-Neto; Dirceu Solé

doi:10.4322/2526-5393.17041027

Artigo Especial

Consenso Brasileiro de Esofagite Eosinofílica: Documento Conjunto da Sociedade Brasileira de Pediatria e Associação Brasileira de Alergia e Imunologia

Brazilian Consensus on Eosinophilic Esophagitis: Joint Statement by the Brazilian Society of Pediatrics and the Brazilian Association of Allergy and Immunology

Cristina Targa Ferreira, Elisa de Carvalho, Carlos Marcelo Timossi, Luciana Rodrigues Silva, Maria do Carmo Barros de Melo, Marise Helena Cardoso Tófoli, Amália Maria Porto Lustosa, Ana Paula Beltran Moschione Castro, Antonio Carlos Pastorino, Ariana Campos Yang, Bruno Acatauassu Paes Barreto, Cibele Dantas Marques, Clóvis Francisco Constantino, Cristina Palmer Barros, Erica Rodrigues Mariano de Almeida Rezende, Fabiane Pomiecinski Frota, Fábio Kuschnir, Fátima Rodrigues Fernandes, Germana Pimentel Stefani, Gustavo Falbo Wandalsen, Helen Santos Osterne, Hildenia Ribeiro, Ingrid Pimentel Cunha Magalhães Souza Lima, Jackeline Motta Franco, José Carlison Santos de Oliveira, José Luiz de Magalhães Rios, José Vicente Spolidoro, Katia Brandt, Luciana Ribeiro, Lucila Camargo Lopes de Oliveira, Luiza Salgado Nader, Margarida Antunes, Mário César Vieira, Mauro Batista de Morais, Mauro Sérgio Toporovski, Natalia Rocha do Amaral Estanislau, Norma Mota de Paula Rubini, Renan Augusto Pereira, Renata Rodrigues Cocco, Ricardo Toma, Roberta Paranhos Fragoso, Rose Marcelino, Simone Carvalho, Herberto José Chong-Neto, Dirceu Solé

http://dx.doi.org/10.4322/2526-5393.17041027 Arq Asma Alerg Imunol, vol.10, n1, e17041027, 2026

PDF

Downloads: 4

Resumo

Documento conjunto da Sociedade Brasileira de Pediatria (SBP) e da Associação Brasileira de Alergia e Imunologia (ASBAI) que estabelece recomendações consensuais para o diagnóstico, tratamento e seguimento da esofagite eosinofílica (EoE) pediátrica, adaptadas à realidade brasileira. Foram formuladas 54 perguntas-chave em três domínios — (I) definição, fisiopatologia, epidemiologia e diagnóstico; (II) tratamento; e (III) seguimento — avaliadas pelo método Delphi em três rodadas por 40 especialistas (20 gastroenterologistas e 20 alergologistas pediátricos), considerando-se consenso ≥ 85% de concordância na escala Likert; a consistência interna foi avaliada pelo alfa de Cronbach.

Palavras-chave

Esofagite eosinofílica; criança; consenso; Técnica Delphi.

Abstract

This joint document from the Brazilian Society of Pediatrics (SBP) and the Brazilian Association of Allergy and Immunology (ASBAI) establishes consensus recommendations for the diagnosis, treatment, and follow-up of pediatric eosinophilic esophagitis (EoE), adapted to the Brazilian setting. Fifty-four key questions were formulated across three domains — (I) definition, pathophysiology, epidemiology, and diagnosis; (II) treatment; and (III) follow-up — and assessed using a three-round Delphi method by 40 specialists (20 pediatric gastroenterologists and 20 pediatric allergists).

Keywords

Eosinophilic esophagitis; child; consensus; Delphi technique.

Referências

1. Dias JA, Oliva S, Papadopoulos A, Thomson M, Gutierrez-Junqueira C, Kalach N, et al. Diagnosis and management of Eosinophilic Esophagitis in children: an update of European Society of Pediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr. 2024;79(2):394-437. https://doi.org/10.1002/jpn3.12188. PMid:38923067.

2. Bortola N, Visaggi P, Penagini R, Annibale B, Svizzero SB, Barbara G, et al. The 1st EoETALY Consensus in the diagnosis and management of Eosinophilic Esophagitis - definition, clinical presentation and diagnosis. Dig Liver Dis. 2024;56(6):951-63. https://doi.org/10.1016/j.dld.2024.02.005. PMid:38423918.

3. Bortola N, Visaggi P, Penagini R, Annibale B, Svizzero SB, Barbara G, et al. The 1st EoETALY Consensus in the diagnosis and management of Eosinophilic Esophagitis - Current treatment and monitoring. Dig Liver Dis. 2024;56(7):1173-84. https://doi.org/10.1016/j.dld.2024.02.020. PMid:38521670.

4. Dellon ES, Muir AB, Katzka DA, Shah SC, Sauer BG, Aceves SS, et al. ACG Clinical Guideline: diagnosis and management of eosinophilic esophagitis. Am J Gastroenterol. 2025;120(1):31-59. https://doi.org/10.14309/ajg.0000000000003194. PMid:39745304.

5. Papagianopoulos K. The ideal and impartial medical expert: tips and tricks for a safe medicolegal practice. J Thorac Dis. 2019;11(Suppl 7):S1009-13. https://doi.org/10.21037/jtd.2019.04.68. PMid:31183183.

6. Gnatzy T, Warth J, von der Gracht H, Darkow I-L. Validating an innovative real-time Delphi approach – A methodological comparison between real-time and conventional Delphi studies. Technol Forecast Soc Change. 2011;78(9):1681-94. https://doi.org/10.1016/j.techfore.2011.04.006.

7. Tanujaya B, Prahmana R, Mumu J. Likert scale in social sciences research: problems and difficulties. FWU J Soc Sci. 2022;16:89-101.

8. Tavakol M, Dennick R. Making sense of Cronbach’s alpha. Int J Med Educ. 2011;2:53-5. https://doi.org/10.5116/ijme.4dfb.8dfd. PMid:28029643.

9. Attwood SE, Smyrk TC, Demeester TR, Jones JB. Esophageal eosinophilia with dysphagia. A distinct clinicopathologic syndrome. Dig Dis Sci. 1993;38(1):109-16. https://doi.org/10.1007/BF01296781. PMid:8420741.

10. Straumann A, Spichtin HP, Bernoulli R, Loosli J, Vögtlin J. Idiopathic eosinophilic esophagitis: a frequently overlooked disease with tipical clinical aspects and discrete endoscopic findings. Schweiz Med Wochenschr. 1994;124(33):1419-29. PMid:7939509.

11. Kelly KJ, Lazenby AJ, Rowe PC, Yardley JH, Perman JA, Sampson HA. Eosinophilic Esophagitis attributed to gastroesophageal reflux improvement with an amino acid-based formula. Gastroenterology. 1995;109(5):1503-12. https://doi.org/10.1016/0016-5085(95)90637-1. PMid:7557132.

12. Dellon ES, Liacouras C, Molina-Infante J, Furuta GT, Spergel JM, Zevit N, et al. Updated international consensus diagnostic criteria of Eosinophilic Esophagitis: proceedings of the AGREE conference. Gastroenterology. 2018;155(4):1022-1033 e10. https://doi.org/10.1053/j.gastro.2018.07.009. PMid:30009819.

13. Lucendo AJ, Molina-Infante J, Arias A, von Arnim U, Bredenoord J, Bussmann C, et al. Guidelines of Eosinophilic Esophagitis: evidence-based statements and recommendations for diagnosis and management in children and adults. United European Gastroenterol J. 2017;5(3):335-58. https://doi.org/10.1177/2050640616689525. PMid:28507746.

14. Linsk SG. Ghaffari G. A review of the evidence linking eosinophilic esophagitis and food allergy. Allergy Asthma Proc. 2015;36(1):26-33. https://doi.org/10.2500/aap.2015.36.3804. PMid:25562553.

15. Clayton F, Fang JC, Gleich GJ, Lucendo AJ, Olalla JM, Vinson LA, et al. Eosinophilic Esophagitis in adults is associated with IgG4 and not mediated by IgE. Gastroenterology. 2014;147(3):602-9. https://doi.org/10.1053/j.gastro.2014.05.036. PMid:24907494.

16. Oliva S, McGowan EC. Associations of eosinophilic gastrointestinal disorders with other gastrointestinal allergic diseases. Immunol Allergy Clin North Am. 2024;44(2):329-48. https://doi.org/10.1016/j.iac.2024.01.005. PMid:38575227.

17. Hill DA, Grundmeier RW, Ramos M, Spergel JM. Eosinophilic Esophagitis is a late manifestation of the allergic march. J Allergy Clin Immunol Pract. 2018;6(5):1528-33. https://doi.org/10.1016/j.jaip.2018.05.010. PMid:29954692.

18. Capucilli P, Cianferoni A, Grundmeier RVV, Spergel J. Comparison of comorbid diagnoses in children with or without EoE in a large population. Allergy Asthma Immunol. 2018;121(6):711-6. https://doi.org/10.1016/j.anai.2018.08.022. PMid:30194971.

19. Visaggi P, Savarino E, Del Corso G, Hunter H, Svizzero FB, Till SJ, et al. Six-food elimination diet is less effective during pollen season in adults with EoE sensitized to pollens. Am J Gastroenterol. 2023;118(11):1957-62. https://doi.org/10.14309/ajg.0000000000002357. PMid:37307575.

20. Kottyan LC, Rothenberg ME. Genetics of Eosinophilic Esophagitis. Mucosal Immunol. 2017;10(3):580-8. https://doi.org/10.1038/mi.2017.4. PMid:28224995.

21. Kottyan LC, Parameswaran S, Weirauch MT, Rothenberg ME, Martin LJ. The genetic etiology of Eosinophilic Esophagitis. J Allergy Clin Immunol. 2020;145(1):9-15. https://doi.org/10.1016/j.jaci.2019.11.013. PMid:31910986.

22. Alexander AS, Martin LJ, Collins MH, Kottyan LC, Sucharew H, He H, et al. Twin and family studies reveal strong environmental and weaker genetic cues explaining heritability of eosinophilic esophagitis. J Allergy Clin Immunol. 2014;134(5):1084-1092.e1. https://doi.org/10.1016/j.jaci.2014.07.021. PMid:25258143.

23. Arias Á, Pérez-Martínez I, Tenías JM, Lucendo AJ. Systematic review with metanalysis: the incidence and prevalence of eosinophilic esophagitis in children and adults in population-based studies. Aliment Pharmacol Ther. 2016;43(1):3-15. https://doi.org/10.1111/apt.13441. PMid:26510832.

24. Lam AY, Lee JK, Coward S, Kaplan GG, Dellon ES, Bredenoord AJ, et al. Epidemiologic burden and projections for esosinophilic esophagitis-associated emergency department visits in the United States 2009-2030. Clin Gastroenterol Hepatol. 2023;21(12):3041-50. https://doi.org/10.1016/j.cgh.2023.04.028. PMid:37164113.

25. Hahn JW, Lee K, Shin JI, Cho SH, Turner S, Shin JU, et al. Global incidence and prevalence of eosinophilic esophagitis, 1976-2022: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2023;21(13):3270-84. https://doi.org/10.1016/j.cgh.2023.06.005. PMid:37331411.

26. Lucendo AJ, Gutierrez-Ramirez L, Tejera-Muñoz A, Molina-Infante J, Arias A. Proton Pump Inhibitors for inducing and maintaining remission in Eosinophilic Esophagitis: an updated systematic review and metaanalysis. Clin Gastroenterol Hepatol. 2025;23(12):2115-2127.e21. https://doi.org/10.1016/j.cgh.2025.01.016. PMid:40089255.

27. Muir A, Falk GW. Eosinophilic Esophagitis: a review. JAMA. 2021;326(13):1310-8. https://doi.org/10.1001/jama.2021.14920. PMid:34609446.

28. Oliva S, Arrigo S, Bramuzzo M, Cisarò F, Dabizzi E, Di Nardo G, et al. Eosinophilic esophagitis in children and adolescents: a clinical practice guideline. Ital J Pediatr. 2025;51(1):242. https://doi.org/10.1186/s13052-025-02056-x. PMid:40702503.

29. Taft TH, Carlson DA, Simons M, Zavala S, Hirano I, Gonsalves N, et al. Esophageal hypervigilance and symptom-specific anxiety in patients with Eosinophilic Esophagitis. Gastroenterology. 2021;161(4):1133-44. https://doi.org/10.1053/j.gastro.2021.06.023. PMid:34153298.

30. Rojler L, Jarber JJ, Butwicka A, Roelstraete B, Ludvigsson JF, et al. Individuals with Eosinophilic Esophagitis are at greater risk of later psyquiatric disorders. Am J Gastroenterol. 2022;177(7):1046-55. https://doi.org/10.14309/ajg.0000000000001749. PMid:35347093.

31. Navarro P, Laserna-Mendieta EJ, Casabona S, Savarino E, Pérez-Fernández MT, Ghisa M, et al. Acurate and timely diagnosis of Eosinophilic Esophagitis improves over time in Europe. An analysis of EoE connect registry. United European Gastroenterol J. 2022;10(5):507-17. https://doi.org/10.1002/ueg2.12240. PMid:35578565.

32. Warners MJ, Nijhuis RABO, de Wijkerslooth LRH, Smout ALPM, Bredenoord AJ. The natural course of Eosinophilic Esophagitis and long-term consequences of undiagnosed disease in a large cohort. Am J Gastroenterol. 2018;113(6):836-44. https://doi.org/10.1038/s41395-018-0052-5. PMid:29700481.

33. Lipka S, Keshishian J, Boyce HW, Estores D, Richter JE. The natural history of steroid-naïve eosinophilic esophagitis in adults treated with endoscopic dilation and proton pump inhibitors therapy over a mean duration of nearly 14 years. Gastrointest Endosc. 2014;80(4):592-8. https://doi.org/10.1016/j.gie.2014.02.012. PMid:24703087.

34. Syed A, Maradey-Romero C, Fass R. The relationship between eosinophilic esophagitis and esophageal cancer. Dis Esophagus. 2017;30(7):1-5. https://doi.org/10.1093/dote/dox050. PMid:30052901.

35. Odiase E, Schwartz A, Souza RH, Martin J, Konda V, Spechler SJ. New Eosinophilic Esophagitis call for change in proton pump inhibitor management before diagnostic endoscopy. Gastroenterology. 2018;154(5):1217-21.e3. https://doi.org/10.1053/j.gastro.2018.03.003. PMid:29510130.

36. Hirano I, Moy N, Heckman MG, Thomas CS, Gonsalves N, Achem SR. Endoscopic assessment of the oesophageal features of eosinophilic oesophagitis: validation of a novel classification and grading system. Gut. 2013;62(4):489-95. https://doi.org/10.1136/gutjnl-2011-301817. PMid:22619364.

37. Nielsen JA, Lager DJ, Lewin M, Rendon G, Roberts CA. The optimal number of biopsy fragments to establish a morphological diagnosis of eosinophilic esophagitis. Am J Gastroenterol. 2014;109(4):515-20. https://doi.org/10.1038/ajg.2013.463. PMid:24445569.

38. Papadopoulou A, Amil-Dias J, Auth MKH, Chehade M, Collins MH, Gupta SK, et al. Joint ESPGHAN/NASPGHAN Guidelines on ChildhoodEosinophilicGastrointestinalDisordersBeyondEosinophilic Esophagitis. J Pediatr Gastroenterol Nutr. 2024;78(1):122-52. https://doi.org/10.1097/MPG.0000000000003877. PMid:38291684.

39. Gentile N, Katzka K, Ravi K, Trenkner S, Enders F, Killian J, et al. Oesophageal narrowing is common and frequently underappreciated at endoscopy in patients with oesophageal eosinophilia. Aliment Pharmacol Ther. 2014;40(11-12):1333-40. https://doi.org/10.1111/apt.12977. PMid:25287184.

40. Menard-Katcher C, Swerdlow MP, Mehta P, Furuta GT, Fenton LZ. Contribution of esophagogram to the evaluation of complicated pediatric eosinophilic esophagitis. J Pediatr Gastroenterol Nutr. 2015;61(5):541-6. https://doi.org/10.1097/MPG.0000000000000849. PMid:25988559.

41. Ghisa M, Laserra G, Marabotto E, Ziola S, Tolone S, de Bortoli N, et al. Achalasia and obstructive motor disorders are not uncommon in patients with eosinophilic esophagitis. Clin Gastroenterol Hepatol. 2021;19(8):1554-63. https://doi.org/10.1016/j.cgh.2020.07.056. PMid:32763482.

42. Savarino EV, Tolone S, Bartolo O, de Cassan C, Caccaro R, Galeazzi F, et al. The GerdQ questionnaire and high-resolution manometry support the hypothesis that proton pump inhibitor-responsive oesophageal eosinophilia is a GERD-related phenomenon. Aliment Pharmacol Ther. 2016;44(5):522-30. https://doi.org/10.1111/apt.13718. PMid:27373195.

43. Almazan E, Liang TZ, Hohl B, Hoskins BJ, Birkness-Gartman JE, Ng K. EndoFLIP distensibility index correlates with histologic findings in children with eosinophilic esophagitis. J Pediatr Gastroenterol Nutr. 2025;80(5):824-31. https://doi.org/10.1002/jpn3.70013. PMid:39959961.

44. Martin LJ, Eby M, He H, Collins MH, Abonia JP, Lee JJ, et al. Pediatric Eosinophilic Esophagitis symptom score (PEESS v2.0) identify histologic and molecular correlates of the key clinical features of disease. J Allergy Clin Immunol. 2015;135(6):1519-28.e8. https://doi.org/10.1016/j.jaci.2015.03.004. PMid:26051952.

45. Santos MFO, Barros CP, Silva CHM, Paro HBMS. Translation and cultural adaptation of the Pediatric Eosinophilic Esophagitis Symptom Score (PEESS v2.0). J Pediatr (Rio J). 2018;94(6):642-51. https://doi.org/10.1016/j.jped.2017.09.004. PMid:29112859.

46. Collins MH, Martin LJ, Alexander ES, Boyd JT, Sheridan R, He H, et al. Newly developed and validated eosinophilic esophagitis histology scoring system and evidence that it outperforms peak eosinophil count for disease diagnosis and monitoring. Dis Esophagus. 2017;30(3):1-8. PMid:26857345.

47. Tamarit-Sebastian S, Ferrer-Soler FM, Lucendo AJ. Current Options and investigational drugs for the treatment of Eosinophilic Esophagitis. Expert Opin Investig Drugs. 2022;31(2):193-210. https://doi.org/10.1080/13543784.2022.2033207. PMid:35072575.

48. Feo-Ortega S, Lucendo AJ. Evidence-based treatments for eosinophilic esophagitis: insights for the clinician. Therap Adv Gastroenterol. 2022;15:17562848211068665. https://doi.org/10.1177/17562848211068665. PMid:35069803.

49. Nader L, Epifanio M, Coelho MG, Steinhaus C, Melere M, Silva CS, et al. High prevalence of responde to PPI treatment in children and adolescents with eosinophilic esophagitis in southern Brazil. Front Allergy. 2024;5:1346843. https://doi.org/10.3389/falgy.2024.1346843. PMid:38650863.

50. Kliewer KL, Abonia JP, Aceves SS, Atkins D, Bonis PA, Capocelli KE, et al. One food versus 4-food elimination diet for pediatric eosinophilic esophagitis: a multisite randomized trial. J Allergy Clin Immunol. 2025;155(2):520-32. https://doi.org/10.1016/j.jaci.2024.08.023. PMid:39233016.

51. Molina‐Infante J, Lucendo AJ. Dietary therapy for eosinophilic esophagitis. J Allergy Clin Immunol. 2018;142(1):41-7. https://doi.org/10.1016/j.jaci.2018.02.028. PMid:29522850.

52. Hirano I, Chan ES, Rank MA, Sharaf RN, Stollman NH, Stukus DR, et al. AGA institute and the joint task force on allergy-immunology practice parameters clinical guidelines for the management of eosinophilic esophagitis. Gastroenterology. 2020;158(6):1776-86. https://doi.org/10.1053/j.gastro.2020.02.038. PMid:32359562.

53. Gutiérrez-Junquera C, Fernández-Fernández S, Cilleruelo ML, Rayo A, Echeverría L, Quevedo S, et al. High prevalence of response to proton-pump inhibitor treatment in children with esophageal eosinophilia. J Pediatr Gastroenterol Nutr. 2016;62(5):704-10. https://doi.org/10.1097/MPG.0000000000001019. PMid:26513622.

54. Gutiérrez-Junquera C, Fernández-Fernández S, Cilleruelo ML, Rayo A, Román E. The role of proton pump inhibitors in the management of pediatric eosinophilic esophagitis. Front Pediatr. 2018;6:119. https://doi.org/10.3389/fped.2018.00119. PMid:29868522.

55. Gutiérrez-Junquera C, Fernández-Fernández S, Cilleruelo ML, Rayo A, Echeverria L, Borrell B, et al. Long-term treatment with proton pump inhibitors is effective in children with Eosinophilic Esophagitis. J Pediatr Gastroenterol Nutr. 2018;67(2):210-6. https://doi.org/10.1097/MPG.0000000000001952. PMid:29509636.

56. Laserna-Mendieta EJ, Casabona S, Guagnozzi D, Savarino E, Perelló A, Guardiola-Arévalo A, et al. Efficacy of proton pump inhibitor therapy for eosinophilic oesophagitis in 630 patients: results from the EoE connect registry. Aliment Pharmacol Ther. 2020;52(5):798-807. https://doi.org/10.1111/apt.15957. PMid:32677040.

57. Sayej WN, Patel R, Baker RD, Tron E, Baker SS. Treatment with high-dose proton pump inhibitors helps distinguish eosinophilic esophagitis from noneosinophilic esophagitis. J Pediatr – Ferreira CT et al. Arq Asma Alerg Imunol – Vol. 10, N° 1, 2026 29 Gastroenterol Nutr. 2009;49(4):393-9. https://doi.org/10.1097/MPG.0b013e31819c4b3e. PMid:19633574.

58. Dranove JE, Horn DS, Davis MA, Kernek KM, Gupta SK. Predictors of response to proton pump inhibitor therapy among children with significant esophageal eosinophilia. J Pediatr. 2009;154(1):96-100. https://doi.org/10.1016/j.jpeds.2008.07.042. PMid:18783791.

59. Schroeder S, Capocelli KE, Masterson JC, Harris R, Protheroe C, Lee JJ, et al. Effect of proton pump inhibitor on esophageal eosinophilia. J Pediatr Gastroenterol Nutr. 2013;56(2):166-72. https://doi.org/10.1097/MPG.0b013e3182716b7a. PMid:23325438.

60. Rea F, Caldaro T, Tambucci R, Romeo EF, Caloisi C, Torroni F, et al. Eosinophilic esophagitis: is it also a surgical disease? J Pediatr Surg. 2013;48(2):304-8. https://doi.org/10.1016/j.jpedsurg.2012.11.006 PMid:23414856.

61. Harris BR, Hon E, Gupta SK. Implementation of guidelines in eosinophilic esophagitis at an academic pediatric practice. Dis Esophagus. 2018;31(8):doy029. https://doi.org/10.1093/dote/doy029.

62. Vieira GG, Ribeiro LBM, Truppel SK, Rosário Filho NA, Vieira MC. Endoscopic and histological characteristics in patients with eosinophilic esophagitis responsive and non-responsive to proton pump inhibitors. J Pediatr (Rio J). 2020;96(5):638-43. https://doi.org/10.1016/j.jped.2019.05.005. PMid:31361987.

63. Rosen I, Mahamed A, Garah J, Magen-Rimon R, Shaoul R. The management and course of eosinophilic oesophagitis in Israeli children. Acta Paediatr. 2021;110(5):1653-7. https://doi.org/10.1111/apa.15746. PMid:33386629.

64. Gutiérrez‐Junquera C, Fernández‐Fernández S, Domínguez‐Ortega G, Miravet V, García-Puig R, Orden-Izquierdo EL, et al. Proton pump inhibitor therapy in pediatric eosinophilic esophagitis: predictive factors and long‐term step‐down eficacy. J Pediatr Gastroenterol Nutr. 2023;76(2):191-8. https://doi.org/10.1097/MPG.0000000000003660. PMid:36416845.

65. Gómez-Torrijos E, Garcia-Rodriguez R, Castro-Jimenez A, Rodríguez-Sanchez J, Méndez Díaz Y, Molina-Infante J. The efficacy of step-down therapy in adult patients with proton pump inhibitor-responsive oesophageal eosinophilia. Aliment Pharmacol Ther. 2016;43(4):534-40. https://doi.org/10.1111/apt.13496. PMid:26662868.

66. Navarro P, Laserna‐Mendieta EJ, Guagnozzi D, Casabona S, Perelló A, Savarino E, et al. Proton pump inhibitor therapy reverses endoscopic features of fibrosis in eosinophilic esophagitis. Dig Liver Dis. 2021;53(11):1479-85. https://doi.org/10.1016/j.dld.2021.05.025. PMid:34120859.

67. Navarro P, Feo‐Ortega S, Casabona‐Francés S, Gutiérrez‐Junquera C, Savarino EV, Amorena E, et al. Determinant factors for firstline treatment choice and effectiveness in pediatric eosinophilic esophagitis: an analysis of the EUREOS EoE CONNECT registry. Eur J Pediatr. 2024;183(8):3567-78. https://doi.org/10.1007/s00431-024-05618-z. PMid:38819501.

68. Laserna-Mendieta EJ, Casabona-Frances S, Amorena E, Savarino E, Perez-Martinez I, Blas-Jhon L, et al. Sex‐related differences in the presentation, management and response to treatment of eosinophilic esophagitis: cross sectional analysis of EoE CONNECT registry. United European Gastroenterol J. 2024;12(10):1388-98. https://doi.org/10.1002/ueg2.12699. PMid:39513462.

69. Oliva S, Dias JA, Rea F, Malamisura M, Espinheira MC, Papadopoulou A, et al. Characterization of eosinophilic esophagitis from the European Pediatric Eosinophilic Esophagitis Registry (pEEr) of ESPGHAN. J Pediatr Gastroenterol Nutr. 2022;75(3):325-33. https://doi.org/10.1097/MPG.0000000000003530. PMid:35706095.

70. Hooflen A, Rea F, Espinheira MC, Dias JA, Romano C, Oliva S, et al. Systemic steroids have a role in treating esophageal strictures in pediatric eosinophilic esophagitis. Dig Liver Dis. 2021;53(3):324-8. https://doi.org/10.1016/j.dld.2020.11.025. PMid:33334703.

71. Moawad FJ, Molina-Infante J, Lucendo AJ, Cantrell SE, Tmanova L, Douglas KM. Systematic review with meta-analysis: endoscopic dilation is highly effective and safe in children and adults with eosinophilic oesophagitis. Aliment Pharmacol Ther. 2017;46(2):96-105. https://doi.org/10.1111/apt.14123. PMid:28513085.

72. Menard-Katcher C, Swerdlow MP, Mehta P, Furuta GT, Fenton LZ. Contribution of esophagram to the evaluation of complicated pediatric eosinophilic esophagitis. J Pediatr Gastroenterol Nutr. 2015;61(5):541-6. https://doi.org/10.1097/MPG.0000000000000849. PMid:25988559.

73. Dellon ES, Rothenberg ME, Collins MH, Hirano I, Chehade M, Bredenoord AJ, et al. Dupilumab in Adults and Adolescents with Eosinophilic Esophagitis. N Engl J Med. 2022;387(25):2317-30. https://doi.org/10.1056/NEJMoa2205982. PMid:36546624.

74. Chehade M, Dellon ES, Spergel JM, Collins MH, Rothenberg ME, Pesek RD, et al. Dupilumab for Eosinophilic Esophagitis in Patients 1 to 11 Years of Age. N Engl J Med. 2024;390(24):2239-51. https://doi.org/10.1056/NEJMoa2312282. PMid:38924731.

75. Agência Nacional de Vigilância Sanitária. Dupixent (dupilumabe): ampliação de uso. 2024 [citado 2025 out 14]. https://www.gov.br/anvisa/pt-br/assuntos/medicamentos/novos-medicamentos-eindicacoes/dupixent-dupilumabe-ampliacao-de-uso-1

76. Lee CJ, Delon ES. Real-world efficacy of dupilumab in severe, treatment-refractory, and fibrostenotic patients with eosinophilic esophagitis. Clin Gastroenterol Hepatol. 2024;22(2):252-8. https://doi.org/10.1016/j.cgh.2023.08.015. PMid:37660770.

77. Chang NC, Thakkar KP, Ketchem CJ, Eluri S, Reed CC, Dellon ES. A gap in care leads to progression of fibrosis in eosinophilic esophagitis patients. Clin Gastroenterol Hepatol. 2022;20(8):1701-8.e2. https://doi.org/10.1016/j.cgh.2021.10.028. PMid:34718172.

78. Straumann A, Spichtin HP, Grize L, Bucher KA, Beglinger C, Simon HU. Natural history of primary eosinophilic esophagitis: a followup of 30 adult patients for up to 11.5 years. Gastroenterology. 2003;125(6):1660-9. https://doi.org/10.1053/j.gastro.2003.09.024. PMid:14724818.

79. Helou EF, Simonson J, Arora AS. 3-yr-follow-up of topical corticosteroid treatment for eosinophilic esophagitis in adults. Am J Gastroenterol. 2008;103(9):2194-9. https://doi.org/10.1111/j.1572-0241.2008.01989.x. PMid:18637093.

80. Dellon ES, Kim HP, Sperry SL, Rybnicek DA, Woosley JT, Shaheen NJ. A phenotypic analysis shows that eosinophilic esophagitis is a progressive fibrostenotic disease. Gastrointest Endosc. 2014;79(4):577-85.e4. https://doi.org/10.1016/j.gie.2013.10.027. PMid:24275329.

81. Bon L, Safroneeva E, Bussmann C, Biedermann L, Schreiner P, Vavricka SR, et al. Close follow-up is associated with fewer stricture formation and results in earlier detection of histological relapse in the long-term management of eosinophilic esophagitis. United European Gastroenterol J. 2022;10(3):308-18. https://doi.org/10.1002/ueg2.12216. PMid:35384368.

Submetido em:
10/03/2026

Aceito em:
10/04/2026